AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9506565 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of weekly oral methotrexate and daily azathioprine (MTX/AZA)
Number of subjects: 30
Study 9506565 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methotrexate with leucovorin rescue (I.V. MTX)
Number of subjects: 30
Study 7827349 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetic patients with microalbuminuria
Number of subjects: 104
Study 7827349 — intervention group
Group type: EXPERIMENTAL
Intervention: Macroalbuminuric patients
Number of subjects: 104
Study 7827349 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic control subjects
Number of subjects: 104
Study 11039059 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated toothpaste systems (five different types)
Number of subjects: 27
Study 11039059 — intervention group
Group type: COMPARATOR
Intervention: Non-fluoridated toothpaste
Number of subjects: 27
Study 30027174 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone (O3) for 60 seconds
Number of subjects: 32
Study 30027174 — intervention group
Group type: COMPARATOR
Intervention: 38% Hydrogen peroxide (H2O2) for 20 minutes
Number of subjects: 32
Study 28685824 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative music application
Number of subjects: 135
Study 28685824 — intervention group
Group type: COMPARATOR
Intervention: No music (control group)
Number of subjects: 135
Study 26578409 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg/day arginyl-fructose
Number of subjects: 49
Study 26578409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 23643233 — intervention group
Group type: EXPERIMENTAL
Intervention: Original 7-point checklist (7PCL)
Number of subjects: 1436
Study 23643233 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted 7-point checklist (7PCL)
Number of subjects: 1436
Study 23643233 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted 7PCL with revised cut-off score of 4
Number of subjects: 1436
Study 21123462 — intervention group
Group type: EXPERIMENTAL
Intervention: Galactose drink
Number of subjects: 14
Study 21123462 — intervention group
Group type: COMPARATOR
Intervention: Glucose drink
Number of subjects: 14
Study 18978625 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional resistance training (CRT)
Number of subjects: 15
Study 18978625 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training (PT)
Number of subjects: 15
Study 16782488 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4-guided HAART (CD4GT)
Number of subjects: 326
Study 16782488 — intervention group
Group type: COMPARATOR
Intervention: Continuous HAART (CT)
Number of subjects: 326
Study 14994604 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin with potassium clavulanate (subgroup A)
Number of subjects: 115
Study 14994604 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime axetil (subgroup B)
Number of subjects: 115
Study 12004793 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 2
Study 12004793 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass surgery (CABG)
Number of subjects: 2
Study 12004793 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician work RVUs for PTCA
Number of subjects: 2
Study 12004793 — intervention group
Group type: EXPERIMENTAL
Intervention: Total RVUs for PTCA
Number of subjects: 2
Study 9260697 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 87
Study 9260697 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 87
Study 8494832 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife-led care
Number of subjects: 3510
Study 8494832 — intervention group
Group type: COMPARATOR
Intervention: Consultant-led care
Number of subjects: 3510
Study 3302875 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (CFX) 1 g/24 h im
Number of subjects: 40
Study 3302875 — intervention group
Group type: COMPARATOR
Intervention: Amikacin (AMK) 500 mg/24 h im
Number of subjects: 40
Study 31992377 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine (BT) 0.6 g/kg DM without RPFA
Number of subjects: 48
Study 31992377 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine (BT) 0.6 g/kg DM with RPFA
Number of subjects: 48
Study 31992377 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine (BT) without RPFA
Number of subjects: 48
Study 31992377 — intervention group
Group type: EXPERIMENTAL
Intervention: RPFA addition
Number of subjects: 48
Study 31992377 — intervention group
Group type: EXPERIMENTAL
Intervention: RPFA or BT addition
Number of subjects: 48
Study 31992377 — intervention group
Group type: EXPERIMENTAL
Intervention: BT addition
Number of subjects: 48
Study 31270037 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided CABG
Number of subjects: 172
Study 31270037 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided CABG
Number of subjects: 172
Study 27138546 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin 10 mg
Number of subjects: 0
Study 27138546 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin 20 mg
Number of subjects: 0
Study 27138546 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin 100 mg
Number of subjects: 0
Study 25040850 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective statement expressing concern about the information
Number of subjects: 157
Study 25040850 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal reference to a written summary of the information
Number of subjects: 157
Study 25040850 — intervention group
Group type: EXPERIMENTAL
Intervention: Both affective qualifier and written summary
Number of subjects: 157
Study 25040850 — intervention group
Group type: COMPARATOR
Intervention: Simple statement (control)
Number of subjects: 157
Study 23381535 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfort-oriented care (default option checked)
Number of subjects: 132
Study 23381535 — intervention group
Group type: EXPERIMENTAL
Intervention: Life-extending care (default option checked)
Number of subjects: 132
Study 23381535 — intervention group
Group type: COMPARATOR
Intervention: Standard advance directive (no options checked)
Number of subjects: 132
Study 21251180 — intervention group
Group type: EXPERIMENTAL
Intervention: LY 0.5/1.0
Number of subjects: 262
Study 21251180 — intervention group
Group type: EXPERIMENTAL
Intervention: LY 1.0/1.0
Number of subjects: 262
Study 21251180 — intervention group
Group type: EXPERIMENTAL
Intervention: LY 1.0/2.0
Number of subjects: 262
Study 19297116 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer agent explanation of consent form
Number of subjects: 0
Study 19297116 — intervention group
Group type: COMPARATOR
Intervention: Human explanation of consent form
Number of subjects: 0
Study 19297116 — intervention group
Group type: COMPARATOR
Intervention: Self-study condition
Number of subjects: 0
Study 17194911 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX (intravenous oxaliplatin plus oral capecitabine; 3‐week cycle for eight cycles)
Number of subjects: 1864
Study 17194911 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX
Number of subjects: 1864
Study 17194911 — intervention group
Group type: COMPARATOR
Intervention: FU/LV (bolus fluorouracil/leucovorin)
Number of subjects: 1864
Study 15537400 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Number of subjects: 0
Study 12407272 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care management (N=31)
Number of subjects: 31
Study 12407272 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced care management (N=94)
Number of subjects: 31
Study 12407272 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive care management (N=74)
Number of subjects: 31
Study 12407272 — intervention group
Group type: COMPARATOR
Intervention: Usual care management (N=192, previous year cohort)
Number of subjects: 31
Study 9703588 — intervention group
Group type: EXPERIMENTAL
Intervention: APAP therapy
Number of subjects: 31
Study 9703588 — intervention group
Group type: COMPARATOR
Intervention: CPAP therapy
Number of subjects: 31
Study 9703588 — intervention group
Group type: COMPARATOR
Intervention: NPSG night
Number of subjects: 31
Study 9703588 — intervention group
Group type: EXPERIMENTAL
Intervention: APAP applied pressure
Number of subjects: 31
Study 9703588 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum APAP applied pressure
Number of subjects: 31
Study 8131529 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol administration
Number of subjects: 66
Study 8131529 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 66
Study 8131529 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy parents of infants without bronchiolitis)
Number of subjects: 66
Study 2683789 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 15
Study 2683789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1101618 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidocaine
Number of subjects: 0
Study 1101618 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 0
Study 377470 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 40
Study 377470 — intervention group
Group type: COMPARATOR
Intervention: N-methyl-d-glucamine salt of indomethacin
Number of subjects: 40
Study 31779693 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised progressive strength training and oral protein supplement during hospitalization and at home 3 days/week for 4 weeks after discharge
Number of subjects: 85
Study 31779693 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised progressive strength training and oral protein supplement
Number of subjects: 85
Study 28109128 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 200
Study 25827594 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus whey protein (WP; 20 g)
Number of subjects: 16
Study 25827594 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose leucine-enriched essential amino acids (LEAA; 3 g, 40% leucine)
Number of subjects: 16
Study 25827594 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 16
Study 23725233 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational CPR video
Number of subjects: 56
Study 23725233 — intervention group
Group type: COMPARATOR
Intervention: Narrative CPR
Number of subjects: 56
Study 21518557 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (rapid steroid reduction to 10 mg/d)
Number of subjects: 30
Study 21518557 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard corticosteroid therapy)
Number of subjects: 30
Study 21518557 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 21518557 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 30
Study 21518557 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 19624581 — intervention group
Group type: COMPARATOR
Intervention: Continuous venovenous hemodiafiltration (CVVHDF)
Number of subjects: 125
Study 19624581 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hemodialysis (IHD)
Number of subjects: 125
Study 19624581 — intervention group
Group type: COMPARATOR
Intervention: CVVHDF
Number of subjects: 125
Study 19624581 — intervention group
Group type: EXPERIMENTAL
Intervention: IHD
Number of subjects: 125
Study 19624581 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 125
Study 17596637 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone
Number of subjects: 69
Study 17596637 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 69
Study 15801334 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 98
Study 15801334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 12066106 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestin-only contraceptive methods
Number of subjects: 319
Study 12066106 — intervention group
Group type: COMPARATOR
Intervention: Nonhormonal methods
Number of subjects: 319
Study 9866771 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time bolus tracking using CARE Bolus software
Number of subjects: 79
Study 9866771 — intervention group
Group type: COMPARATOR
Intervention: Fixed, preselected start delay of 80 s (Control)
Number of subjects: 79
Study 7557557 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (150 mg/day)
Number of subjects: 48
Study 7557557 — intervention group
Group type: EXPERIMENTAL
Intervention: Picotamide (450 mg/day)
Number of subjects: 48
Study 7557557 — intervention group
Group type: EXPERIMENTAL
Intervention: Picotamide (900 mg/day)
Number of subjects: 48
Study 7557557 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus Picotamide (150 mg/day and 450 mg/day respectively)
Number of subjects: 48
Study 7557557 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 48
Study 2709254 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual reintroduction to normal milk (slow regrade)
Number of subjects: 68
Study 2709254 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate return to full-strength formula
Number of subjects: 68
Study 2709254 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid regrade to a hypoallergenic whey hydrolysate formula
Number of subjects: 68
Study 2709254 — intervention group
Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 68
Study 798576 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 51
Study 798576 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 51
Study 798576 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 51
Study 798576 — intervention group
Group type: COMPARATOR
Intervention: Normotensive controls
Number of subjects: 51
Study 31782945 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPS added to qSOFA (T-qSOFA)
Number of subjects: 821
Study 30918121 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate PrEP (IMM)
Number of subjects: 239
Study 30918121 — intervention group
Group type: COMPARATOR
Intervention: Deferred PrEP (DEF)
Number of subjects: 239
Study 30918121 — intervention group
Group type: COMPARATOR
Intervention: Deferred PrEP (DEF) with self-reported diagnosis of syphilis, rectal chlamydia (CT) or rectal gonorrhoea (GC) in the previous 12 months
Number of subjects: 239
Study 30918121 — intervention group
Group type: COMPARATOR
Intervention: Deferred PrEP (DEF) with receptive anal intercourse without a condom (ncRAI) with two or more partners in the previous 3 months
Number of subjects: 239
Study 30918121 — intervention group
Group type: COMPARATOR
Intervention: Deferred PrEP (DEF) lacking both syphilis/rectal CT/GC and multiple ncRAI partners
Number of subjects: 239
Study 28135751 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable sutures
Number of subjects: 161
Study 28135751 — intervention group
Group type: COMPARATOR
Intervention: Non-absorbable sutures
Number of subjects: 161
Study 24652860 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 50
Study 24652860 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 50
Study 24652860 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study 23258319 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard parapatellar (SP) surgical approach
Number of subjects: 60
Study 23258319 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-parapatellar (MP) surgical approach
Number of subjects: 60
Study 21241906 — intervention group
Group type: EXPERIMENTAL
Intervention: Plate-haptic acrylic IOL (Acri.Smart 46S)
Number of subjects: 40
Study 21241906 — intervention group
Group type: COMPARATOR
Intervention: 3-piece loop-haptic acrylic IOL (Acri.Lyc 53N)
Number of subjects: 40
Study 21241906 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IOLs
Number of subjects: 40
Study 19473224 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual art therapy sessions for 1 h/week (n = 20)
Number of subjects: 41
Study 19473224 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 21)
Number of subjects: 41
Study 16984699 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (40 children completed the program)
Number of subjects: 121
Study 16984699 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 121
Study 16984699 — intervention group
Group type: COMPARATOR
Intervention: Control group (155 children)
Number of subjects: 121
Study 16984699 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-participants in intervention (74 children)
Number of subjects: 121
Study 16984699 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-participants in intervention
Number of subjects: 121
Study 15024499 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet released intraoperatively after prosthetic components settled and hemostasis done
Number of subjects: 76
Study 15024499 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet released after wound closure and compressive bandage applied
Number of subjects: 76
Study 11829723 — intervention group
Group type: EXPERIMENTAL
Intervention: Deoxycholate or liposomal formulations of amphotericin B
Number of subjects: 0
Study 11829723 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 0
Study 11829723 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 0
Study 11829723 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation triazoles and echinocandins
Number of subjects: 0
Study 9522136 — intervention group
Group type: EXPERIMENTAL
Intervention: haemodilution group
Number of subjects: 60
Study 9522136 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 60
Study 7857501 — intervention group
Group type: EXPERIMENTAL
Intervention: hypericum extract LI 160
Number of subjects: 72
Study 7857501 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 72
Study 2676609 — intervention group
Group type: EXPERIMENTAL
Intervention: Coumarin (1,2‐benzopyrone) daily oral dose of 50 mg
Number of subjects: 27
Study 2676609 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 27
Study 16792 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 20
Study 16792 — intervention group
Group type: COMPARATOR
Intervention: Methyprylon 300 mg
Number of subjects: 20
Study 31964678 — intervention group
Group type: EXPERIMENTAL
Intervention: QbTest plus usual care
Number of subjects: 60
Study 31964678 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 30686609 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg
Number of subjects: 88
Study 30686609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 29999197 — intervention group
Group type: EXPERIMENTAL
Intervention: Abametapir lotion, 0.74%
Number of subjects: 704
Study 29999197 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 704
Study 27603423 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral oestrogen
Number of subjects: 900
Study 27603423 — intervention group
Group type: COMPARATOR
Intervention: Total androgen blockade
Number of subjects: 900
Study 24531755 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C-rich apple juice (VCR) - 60 mg/L vitamin C and 510 mg catechin equivalent/L
Number of subjects: 20
Study 24531755 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich apple juice (PR) - 22 mg/L vitamin C and 993 mg catechin equivalent/L
Number of subjects: 20
Study 23094031 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous blue light exposure (GOLite, Philips, 468 nm)
Number of subjects: 40
Study 23094031 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (2*200 mg)
Number of subjects: 40
Study 23094031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 20368553 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (10 mg/kg every 2 weeks) plus interferon alfa-2a (9 MIU subcutaneously three times a week)
Number of subjects: 649
Study 20368553 — intervention group
Group type: COMPARATOR
Intervention: Interferon plus placebo
Number of subjects: 649
Study 20368553 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus IFN (postprotocol therapy including a tyrosine kinase inhibitor)
Number of subjects: 649
Study 20368553 — intervention group
Group type: COMPARATOR
Intervention: IFN plus placebo (postprotocol therapy including a tyrosine kinase inhibitor)
Number of subjects: 649
Study 17464455 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI+H2RA group (roxatidine given)
Number of subjects: 15
Study 17464455 — intervention group
Group type: EXPERIMENTAL
Intervention: None+H2RA group (roxatidine given)
Number of subjects: 15
Study 17464455 — intervention group
Group type: COMPARATOR
Intervention: None+None group (roxatidine not given)
Number of subjects: 15
Study 15542794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold air challenge (CACh)
Number of subjects: 40
Study 15542794 — intervention group
Group type: COMPARATOR
Intervention: Dry air challenge (DACh)
Number of subjects: 40
Study 12045046 — intervention group
Group type: EXPERIMENTAL
Intervention: Heidelberg Retina Tomograph I (HRT)
Number of subjects: 55
Study 10372726 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist (Nal‐Glu; 150 microg/kg) during midfollicular phase (MFP)
Number of subjects: 19
Study 10372726 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist (Nal‐Glu; 150 microg/kg) during late follicular phase (LFP)
Number of subjects: 19
Study 10372726 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist (Nal‐Glu; 150 microg/kg) during midluteal phase (MLP)
Number of subjects: 19
Study 7752180 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking without caffeine
Number of subjects: 6
Study 7752180 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee plus cigarette smoking
Number of subjects: 6
Study 7752180 — intervention group
Group type: COMPARATOR
Intervention: Placebo (abstention from smoking and caffeine)
Number of subjects: 6
Study 2115446 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal solution (100 mg flecainide)
Number of subjects: 7